Key Facts
Latest information about our company.
Global Business
Updated January 2017
Chief Executive Officer:
Headquarters:
Princeton, New Jersey, USA
Business:
Biopharmaceuticals
Web Address:
NYSE Listing:
BMY
Net Global Sales:
$19.4 billion in 2016
R&D Investment:
$4.94 billion which included the discovery and development of new medicines for patients
Principal Locations:
Local Business
Updated July 2017
Australian head office:
Level 2, 4 Nexus Court,
Mulgrave, Victoria 3170
Australia
Mulgrave, Victoria 3170
Australia
Key Products in Market:
BARACLUDE® (entecavir)
DAKLINZA™ (daclatasvir)
ELIQUIS® (apixaban)
EVOTAZ® (atazanavir & cobicistat)
OPDIVO® (nivolumab)
ORENCIA® (abatacept)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUNVEPRA® (asunaprevir)
YERVOY® (ipilimumab)
DAKLINZA™ (daclatasvir)
ELIQUIS® (apixaban)
EVOTAZ® (atazanavir & cobicistat)
OPDIVO® (nivolumab)
ORENCIA® (abatacept)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUNVEPRA® (asunaprevir)
YERVOY® (ipilimumab)